Single User License
INR 133820
Site License
INR 267640
Corporate User License
INR 401460

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Allergic Asthma-Pipeline Review, H1 2015

Allergic Asthma-Pipeline Review, H1 2015

  Request for Sample Report

Executive Summary

Allergic Asthma-Pipeline Review, H1 2015


Global Markets Direct's, 'Allergic Asthma-Pipeline Review, H1 2015', provides an overview of the Allergic Asthma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Allergic Asthma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Allergic Asthma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Allergic Asthma Overview 10

Therapeutics Development 11

Pipeline Products for Allergic Asthma-Overview 11

Pipeline Products for Allergic Asthma-Comparative Analysis 12

Allergic Asthma-Therapeutics under Development by Companies 13

Allergic Asthma-Therapeutics under Investigation by Universities/Institutes 16

Allergic Asthma-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Allergic Asthma-Products under Development by Companies 20

Allergic Asthma-Products under Investigation by Universities/Institutes 22

Allergic Asthma-Companies Involved in Therapeutics Development 23

ALK-Abello A/S 23

Allergopharma Joachim Ganzer KG 24

Array BioPharma Inc. 25

Aslan Pharmaceuticals Pte. Ltd. 26

Asmacure Ltee 27

BioTech Tools s.a. 28

Fountain Biopharma Inc. 29

Genentech, Inc. 30

Infinity Pharmaceuticals, Inc. 31

Kineta, Inc. 32

Marinomed Biotechnologie GmbH 33

NeoPharm Co., Ltd. 34

Novartis AG 35

Nuvo Research Inc. 36

Panacea Biotec Limited 37

Peptinnovate Limited 38

Pharmaxis Limited 39

Portola Pharmaceuticals, Inc. 40

Protectimmun GmbH 41

Pulmatrix, Inc. 42

Stallergenes S.A. 43

sterna biologicals Gmbh & Co KG 44

Verona Pharma Plc 45

Allergic Asthma-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(fluticasone propionate + salmeterol xinafoate)-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Acaroid-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AcTMP-1-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

allergenic pollen extract of timothy-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Arabinogalactan-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ARRY-502-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

ASLAN-004-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

ASM-024-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ASM-8-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

dalazatide-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Drug to Inhibit PI3 Kinase Delta for Asthma-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

duvelisib-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

E-3.56-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

FB-825-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

fevipiprant-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

hdm-ASIT-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Lactococcus lactis G121-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

ligelizumab-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

MAM-06301-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

MK-8237-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

omalizumab biosimilar-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

omalizumab biosimilar-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

PIN-201601-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

PRT-2607-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

quilizumab-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

RPL-554-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

S-524101-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

SB-010-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

SG-100-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Small Molecule for Allergic Asthma-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecule for Allergic Asthma-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules for Allergic Asthma-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecules to Inhibit C-Rel for Central Nervous System, Immunology, Musculoskeletal, Oncology, Respiratory and Metabolic Disorders-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Small Molecules to Inhibit CaMKII for Allergic Asthma-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

timothy grass pollen allergen extract-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Vaccine for Allergic Rhinitis and Allergic Asthama-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

WF-10-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

WF-10 liposomal-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Allergic Asthma-Recent Pipeline Updates 109

Allergic Asthma-Dormant Projects 131

Allergic Asthma-Discontinued Products 134

Allergic Asthma-Product Development Milestones 135

Featured News & Press Releases 135

Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 135

May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 136

May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 137

Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 137

Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 138

Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 139

Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 139

Appendix 141

Methodology 141

Coverage 141

Secondary Research 141

Primary Research 141

Expert Panel Validation 141

Contact Us 141

Disclaimer 142

List of Tables

Number of Products under Development for Allergic Asthma, H1 2015 11

Number of Products under Development for Allergic Asthma-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Allergic Asthma-Pipeline by ALK-Abello A/S, H1 2015 23

Allergic Asthma-Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 24

Allergic Asthma-Pipeline by Array BioPharma Inc., H1 2015 25

Allergic Asthma-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 26

Allergic Asthma-Pipeline by Asmacure Ltee, H1 2015 27

Allergic Asthma-Pipeline by BioTech Tools s.a., H1 2015 28

Allergic Asthma-Pipeline by Fountain Biopharma Inc., H1 2015 29

Allergic Asthma-Pipeline by Genentech, Inc., H1 2015 30

Allergic Asthma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 31

Allergic Asthma-Pipeline by Kineta, Inc., H1 2015 32

Allergic Asthma-Pipeline by Marinomed Biotechnologie GmbH, H1 2015 33

Allergic Asthma-Pipeline by NeoPharm Co., Ltd., H1 2015 34

Allergic Asthma-Pipeline by Novartis AG, H1 2015 35

Allergic Asthma-Pipeline by Nuvo Research Inc., H1 2015 36

Allergic Asthma-Pipeline by Panacea Biotec Limited, H1 2015 37

Allergic Asthma-Pipeline by Peptinnovate Limited, H1 2015 38

Allergic Asthma-Pipeline by Pharmaxis Limited, H1 2015 39

Allergic Asthma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 40

Allergic Asthma-Pipeline by Protectimmun GmbH, H1 2015 41

Allergic Asthma-Pipeline by Pulmatrix, Inc., H1 2015 42

Allergic Asthma-Pipeline by Stallergenes S.A., H1 2015 43

Allergic Asthma-Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 44

Allergic Asthma-Pipeline by Verona Pharma Plc, H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Allergic Asthma Therapeutics-Recent Pipeline Updates, H1 2015 109

Allergic Asthma-Dormant Projects, H1 2015 131

Allergic Asthma-Dormant Projects (Contd..1), H1 2015 132

Allergic Asthma-Dormant Projects (Contd..2), H1 2015 133

Allergic Asthma-Discontinued Products, H1 2015 134

List of Figures

Number of Products under Development for Allergic Asthma, H1 2015 11

Number of Products under Development for Allergic Asthma-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 48

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

ALK-Abello A/S

Allergopharma Joachim Ganzer KG

Array BioPharma Inc.

Aslan Pharmaceuticals Pte. Ltd.

Asmacure Ltee

BioTech Tools s.a.

Fountain Biopharma Inc.

Genentech, Inc.

Infinity Pharmaceuticals, Inc.

Kineta, Inc.

Marinomed Biotechnologie GmbH

NeoPharm Co., Ltd.

Novartis AG

Nuvo Research Inc.

Panacea Biotec Limited

Peptinnovate Limited

Pharmaxis Limited

Portola Pharmaceuticals, Inc.

Protectimmun GmbH

Pulmatrix, Inc.

Stallergenes S.A.

sterna biologicals Gmbh & Co KG

Verona Pharma Plc

Allergic Asthma Therapeutic Products under Development, Key Players in Allergic Asthma Therapeutics, Allergic Asthma Pipeline Overview, Allergic Asthma Pipeline, Allergic Asthma Pipeline Assessment

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]